SINGAPORE--(BUSINESS WIRE)--MP Biomedicals Asia Pacific PTE LTD, a subsidiary of MP Biomedicals LLC, a leading multinational company focused in Life Sciences and Diagnostics has received approval from The National Health Surveillance Agency (ANVISA) to market its HIV Blot 2.2, HIV Blot 1.3, HCV Blot 3.0 and HTLV - I/II ELISA 4.0 diagnostic tests in Brazil. This is MP Biomedicals second approval from ANVISA, with the first coming in August of 2010 when the company’s Assure Dengue IgA rapid test was cleared for marketing.
